{"name":"Donald B. Kohn, M.D.","slug":"donald-b-kohn-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADA gene transfer","genericName":"ADA gene transfer","slug":"ada-gene-transfer","indication":"Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency","status":"phase_2"}]}],"pipeline":[{"name":"ADA gene transfer","genericName":"ADA gene transfer","slug":"ada-gene-transfer","phase":"phase_2","mechanism":"ADA gene transfer involves the introduction of a healthy copy of the ADA gene into a patient's hematopoietic stem cells to treat ADA-SCID.","indications":["Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPSjJhOWFRQ29xSy01OUVhWFlRRUdaWDdJRWZFOXlDT1BEVjhxN08xUkFzbjZWNjlvWjFWUk1la21HT0w1d2Qyc3hGSXRCYnVyeU5LN0JyM0xWemxlaVdsYTdSOU5wSURSd0pKeVRrcG5sVXRGVU9KRk8yZ1R4NnU4aXAyMVRpR1YzV1ZKQ0lRdnVJdVMxYUUzTFRjRDRseGlaZUI0SjI1S3lOUVVQTDJxNTJlUGZwSWc?oc=5","date":"2026-04-03","type":"regulatory","source":"theindianpractitioner.com","summary":"FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for LAD-I - theindianpractitioner.com","headline":"FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for LAD-I","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQb3pwVE5RSS1EdU5MNFZzVDN6d3JodDlIV09mYXo5V3NQeWl1em55dWtLY3c0VVhiX00yaGVBVi1IMFNqazhkbVRUclRNamV6LUo2X3J1LUF5dkR6YlBtZmo4cnhXWkhpYktZMEtCempJdV9XUnQ0Y29fZ1hSaVNpazNnY1JhMlBIaWNoSDBmaFRHNlU3YjhrSjVPa1dpVHMxSmxBRWhjbEJqZmltYUl6Y2R3TW9CWlo3alBDMDR6eEpVaUxhb0N3MDMzSnBheHBaSkRvOHpnWW52U1NRRFNWSE5tWmRQTUxYNEhwYURDTWdnS2JuWktyODhKZTdWa2FzdUtXRDBqcnNVX1FpVU5ORnluaERLZw?oc=5","date":"2026-03-27","type":"regulatory","source":"Business Wire","summary":"Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire","headline":"Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficie","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPcW1DaU9nb2N4aFRkNjZBMkF6VjZzSGhhRzFtajFTb0NUVEtaMEYxYTdVSHFWbmVMMHdTUFEzUk9GM3dleVBLaEJXQ1VTTzU5bWtrQjVWZTZTSW9NZmlvOVFSdUpKSnJwcXRqVkpHX1RweW56eUtwYk1fS0xMTXJiSUl0empOV3ZVeTM0Rll5Y05SZzk5X3c?oc=5","date":"2026-03-27","type":"regulatory","source":"UCLA Health","summary":"FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder - UCLA Health","headline":"FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQM3NPc2ZGWkJoMmltSDRrUWJlSG8zakZpRlVHWlF6WFFJU0tKaDNVNWZldkItRmtyN29ORm5CWEdvNl8wVXBCYkFqMnhnVzFLaUdtMEZ1ZHVsVzhlb1JpS0h6ckM2ekRHTVhoOFJMWlFFVG04SWl3aGJvQXk1ZWNwWVhVRE11QQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Traders Union","summary":"Gene therapy for inborn immune errors takes center stage in Rocket Pharmaceuticals expert forum - Traders Union","headline":"Gene therapy for inborn immune errors takes center stage in Rocket Pharmaceuticals expert forum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSmJXdjFxNk1ubXZEckctbTJQY2YxUzBILS10R0tudWNwaERxbVhmUzU5RlQ3Y1FuUkNJY3FyWmlDcVVEUTRjN0N6YnR2TVpiMTBuMWlRRi16Y1RLd1JXQlNEQ0UxancxVjctdXdBT1pyTU9xbktIanE0NGZKSUVrVUJjTFR6UmNuUUdLSjFEOTloSXBWSmNLTF9lNXd4bXVQaEdXQ1lrckExVVoxRkMwZFJEOHVLQU1LMXVRZmp3?oc=5","date":"2025-10-30","type":"pipeline","source":"BioSpace","summary":"Rarity PBC Raises $4.6 Million Seed Financing to Advance Gene Therapy for ADA-SCID - BioSpace","headline":"Rarity PBC Raises $4.6 Million Seed Financing to Advance Gene Therapy for ADA-SCID","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXQWppb3U4bHdSb2REOXhMNUVGT1B6MDhMX1N6dndXVmVoRGpkX3gwSUVIU1ZkQUZPczI1WEFTMVRvR2NEMUJyUEI1TVltQk5NRExSX3JKNGwzem42WWNV?oc=5","date":"2025-10-15","type":"pipeline","source":"NEJM","summary":"Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency - NEJM","headline":"Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNbzdQNmlXYmZnZnJQVDYxc0NnTFBra2RyS0lvdXZNUnBXLXljYXdTUExZNEJzQ3hxc0xmRlc3YnBMMHdNUHkwZ2ZfUjQyaDRtQnFNMHN5cm5JZmFnakRNNy1heTgzLTlzMXh0bU8wU01GbmhIbWVIenZVbVNEWnQybEFGRDVjQWhhYTNpd2YxOXRrZzZXblAxREhYQ1B3YmFHZ05XR2RoOEZDU21WUGRrNEVPM3NpVDBXMW50MUJxWnMwQVBKNG5Ccw?oc=5","date":"2025-10-15","type":"regulatory","source":"Inside Precision Medicine","summary":"ADA-SCID Gene Therapy: Children Remain Cured After 10+ Years - Inside Precision Medicine","headline":"ADA-SCID Gene Therapy: Children Remain Cured After 10+ Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOZUIyRzVma2dkNjBSLThQeWl4ekRmbmlDVi02RGtnN3hCa2Jvc051dzNnOFRGZ0lDMnZzeEpkVUVhQm9VYTZabkxWVTQyQUk2bEhrRy1YS1l0NVBpZWtrLU9kRE9CY05BMWR1djFsRVFxQVBINjY1QlkzV09GSVJYWjlBNHNQaFd1?oc=5","date":"2025-10-14","type":"regulatory","source":"CGTLive®","summary":"BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again - CGTLive®","headline":"BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again - CGTLive®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOVHlNSkZZQXNKalZGUm5mM2xRN203V2pBRF9pemYyMk9PeGkxRGNnX2pTN0o0U3MtbEZHVFZqMzkwbjEteGhONHlkSjl4WVYxY3dlaEVGamRIZEt3d0lOMkxoV2FjR0J6Rlc5cXVnWnI3aVBsZ2dpUlMxdEZWLTZnTHRMdFZndHN0dVRSNGRvS2RiVzhwQ3htWnBBdw?oc=5","date":"2025-04-30","type":"pipeline","source":"UCLA Health","summary":"Gene therapy restores immune function and extends lives of children with rare immune disorder - UCLA Health","headline":"Gene therapy restores immune function and extends lives of children with rare immune disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFB6MEZzbmJ1VUU4d3U1UkNJdElXY2xSeDBoXy10MXp6YW1UdmxpTld3a3ctOUF0N1djcFlzaXdzeG5id2U0R2VKWkxKcV9aTmtkSTZDWQ?oc=5","date":"2024-12-25","type":"pipeline","source":"Oncodaily","summary":"Exploring Advances in ADA-SCID Gene Therapy: An Interview with Dr. Donald Kohn - Oncodaily","headline":"Exploring Advances in ADA-SCID Gene Therapy: An Interview with Dr. Donald Kohn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNMnRmclpjVjBKYVc1OFdHQllYb3Fsd2pWVTZkYkM0X216RXgxQXlqa3BtNThlNk5FQ2xMYTFjTEV0SzYwTk1fazcxbWNJWklONDFKYmQ2VXFvbXkwOTlKQWdYTkZPdVJlS3d6NXhNeUhYNmNQSzRXMjNSSGVpT2FvQ2FLejFNM1RfaXVMRl9pWUEwRXlseDVSNlBaUGpiUQ?oc=5","date":"2024-11-21","type":"regulatory","source":"UCLA Health","summary":"Donald Kohn awarded $14.7M CIRM grant to advance ADA-SCID gene therapy toward FDA approval - UCLA Health","headline":"Donald Kohn awarded $14.7M CIRM grant to advance ADA-SCID gene therapy toward FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE50TDhGZzFaR2l4Z2hERllXcFU2d1dJTENiVkpTSWJ2T2dVYlMtYVRCMHFXZGVpMDdPYkxDT2F2M2YxMktXRjlsMDZaVHN6Qmh1MXphNWkyazFrU1Y1WWl1MXFZM1V4NVM4ZmVVV1B3WnNVWVhfRV9GaFpNNA?oc=5","date":"2024-06-28","type":"regulatory","source":"CGTLive®","summary":"FDA Issues CRL for Rocket’s LAD-I Gene Therapy - CGTLive®","headline":"FDA Issues CRL for Rocket’s LAD-I Gene Therapy - CGTLive®","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}